A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

NCT ID: NCT00000943

Last Updated: 2021-10-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2005-11-30

Brief Summary

The purpose of this study is to determine the effects of an HIV vaccine (Remune) on the immune system. This study involves patients who have received at least 60 weeks of anti-HIV therapy, either alone or in combination with IL-2, while enrolled in ACTG 328.

Remune is an experimental HIV vaccine. To see how the body's immune system reacts, this vaccine will be given with 1 to 3 other vaccines, and skin tests will monitor the body's reaction.

Detailed Description

Proliferative responses to HIV antigens are either absent or of small magnitude in HIV-infected patients, even in the early stages of infection when vigorous proliferative responses to recall antigens are still seen. Remune consists of an inactivated, gp120-depleted virus intended to stimulate HIV-specific immune responses. Remune has been reported to increase lymphocyte proliferative responses to HIV antigens in patients with high CD4 cell counts. Many other T-cell-dependent responses are also impaired in HIV-infected patients, such as after vaccination with hepatitis A or B vaccine. In this study, patients with moderately advanced HIV disease who have already received 52 weeks of either HAART or HAART plus IL-2 are vaccinated with Remune and a control recall immunogen, tetanus toxoid (TT), to evaluate whether these patients can develop new CD4 T-cell and CD8 T-cell responses to HIV-related antigens. The antibody response to hepatitis A and hepatitis B vaccinations also will be explored.

Fifty patients are enrolled in this substudy; 17 from the HAART only arm (Arm I of ACTG 328) and 33 from the HAART plus either CIV or subcutaneous IL-2 arms (Arms II and III of ACTG 328). All patients are vaccinated 3 times with Remune and twice with TT. If patients are hepatitis A total antibody negative, they receive hepatitis A vaccine twice. Additionally, if patients are hepatitis B surface antigen negative, hepatitis B core antibody and surface antibody negative, they receive hepatitis B vaccine 3 times. Patients who are negative for all hepatitis markers receive hepatitis A and B vaccines.

Week 0 of A5046s begins at or after Week 64 of ACTG 328 (for patients in the HAART-only arm) or 4 weeks after the initiation of the seventh or any subsequent IL-2 cycle of ACTG 328 (for patients in any of the IL-2-containing arms). [AS PER AMENDMENT 9/16/99: Patients can be screened through Week 124 of ACTG 328.] Patients receive Remune at Weeks 0, 8, and 16 and TT at Weeks 0 and 8. Hepatitis A and/or B vaccines are also given at these times, if indicated. Blood and skin tests are performed at Weeks 0, 8, 16, and 24 to measure immune response and lymphocyte proliferative responses.

Conditions

HIV Infections

Keywords

Lymphocytes; Interleukin-2; Drug Therapy, Combination; AIDS Vaccines; CD4 Lymphocyte Count; Cell Division; HIV Core Protein p24; Anti-HIV Agents; HIV Therapeutic Vaccine

Study Design

• Primary Study Purpose: TREATMENT

Interventions

Tetanus Toxoid Vaccine

Intervention Type: BIOLOGICAL

Hepatitis A Vaccine (Inactivated)

Intervention Type: BIOLOGICAL

HIV-1 Immunogen

Intervention Type: BIOLOGICAL

Hepatitis B Vaccine (Recombinant)

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Have completed at least 60 weeks of treatment on ACTG 328.
• Are willing to continue on their assigned ACTG 328 treatment until after they have completed 24 weeks on this substudy.
• Have a viral load less than or equal to 2,000 copies/ml.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have an active opportunistic (HIV-related) infection.
• Are pregnant or breast-feeding.
• Have taken or are taking certain medications that are prohibited.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hernan Valdez

Role: STUDY_CHAIR

Michael Lederman

Role: STUDY_CHAIR

Locations

Univ. of Iowa Healthcare, Div. of Infectious Diseases

Iowa City, Iowa, United States

NY Univ. HIV/AIDS CRS

New York, New York, United States

Countries

United States

References

Valdez H, Mitsuyasu R, Landay A, Sevin AD, Chan ES, Spritzler J, Kalams SA, Pollard RB, Fahey J, Fox L, Namkung A, Estep S, Moss R, Sahner D, Lederman MM. Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis. 2003 Jan 15;187(2):320-5. doi: 10.1086/346056. Epub 2003 Jan 6.

Reference Type: BACKGROUND

PMID: 12552459 (View on PubMed)

Other Identifiers

ACTG 328 (Main Study)

Identifier Type: -

Identifier Source: secondary_id

AACTG A5046s

Identifier Type: -

Identifier Source: secondary_id

10794

Identifier Type: REGISTRY

Identifier Source: secondary_id

ACTG A5046s

Identifier Type: -

Identifier Source: secondary_id

A5046s

Identifier Type: -

Identifier Source: org_study_id